The patent owner of the EpiPen is the target of our wrath over its price. However, as I noted in a previous post, there is much more to the story than greed. That includes the US regulatory process which enables such actions in the absence of competition.
Consider this from a Wall Street Journal article September 1, 2016.
Yet in Europe, EpiPen competes with several devices at a fraction of its U.S. list price of $608.61 per pair. Denmark’s ALK-Abello, which specializes in allergy therapies, sells the Jext pen for $34 to $67 throughout Europe, and is interested in selling it in the U.S. “Our decision will be determined by what it takes to obtain FDA approval,” says a spokesman.
This is just one example of our processes inhibiting competition. Many people hold European health care as a models up for us to follow; here is an example of how Europeans do things differently.
QUINNSCOMMENTARY 